The development of next-generation antithrombotic therapeutics-particularly monoclonal antibodies targeting coagulation factors such as Factor XI (FXI)-requires precise evaluation of the balance between antithrombotic efficacy and bleeding liability. This dual assessment remains a central challenge in preclinical development, especially for biologics with complex mechanisms of action.
Non-human primates (NHPs) offer a highly translatable model system due to their close physiological homology to humans in both coagulation and immune pathways. As a result, NHP-based models are increasingly regarded as critical tools for predicting clinical outcomes of antibody-based therapeutics.
Prisys Biotechnologies, an AAALAC-accredited translational research organization, has established a robust platform for evaluating bleeding and thrombosis risks in cynomolgus monkeys. Its integrated AV-shunt thrombosis and venous bleeding models have supported multiple IND submissions and contributed to peer-reviewed publications, enabling scientifically rigorous and regulatory-aligned decision-making.
Quantitative Assessment of Antithrombotic Efficacy: The NHP AV-Shunt Model
The arteriovenous (AV) shunt thrombosis model in NHPs enables simultaneous activation of primary and secondary hemostasis, incorporating both platelet aggregation and coagulation cascade dynamics. This dual-pathway activation makes it particularly suitable for evaluating anticoagulant biologics.
Under anesthesia, a controlled extracorporeal circuit is established between the femoral artery and femoral vein. Blood is allowed to circulate through the shunt for a defined period, typically 15 minutes, during which thrombus formation occurs on a standardized substrate (e.g., surgical thread). The thrombus-bearing material is then collected, dried, and weighed.
The primary pharmacodynamic endpoint-net clot weight-is calculated by subtracting the baseline weight of the substrate. This quantitative metric provides a sensitive and dose-dependent measure of antithrombotic activity, enabling clear differentiation between therapeutic candidates and dosing regimens.
Importantly, this model has demonstrated strong reproducibility and translational relevance, supporting its use in regulatory submissions.
Parallel Evaluation of Bleeding Risk: Forearm Vein Bleeding Model
To complement efficacy assessment, a standardized forearm vein bleeding model is employed to quantify bleeding risk under controlled conditions.
A small, reproducible incision is created in the forearm vein, and blood is gently absorbed using filter paper without applying pressure to the wound. Bleeding time and total blood loss are recorded with high precision.
- Compared to traditional models such as tail transection or fingertip bleeding, this approach offers reduced variability and improved repeatability.
- It allows for serial measurements at multiple post-dose time points, enabling detailed characterization of the temporal effects of antibody therapeutics on hemostasis.
This feature is particularly valuable for biologics with long half-lives or delayed pharmacodynamic responses.
Integrated Clinical Pathology and Coagulation Analysis
In addition to in vivo endpoints, comprehensive in vitro coagulation assays are incorporated to provide mechanistic insights and support translational interpretation.
At Prisys, these analyses typically include dynamic monitoring of activated partial thromboplastin time (aPTT) and prothrombin time (PT), alongside rotational thromboelastometry (ROTEM) for real-time evaluation of clot formation kinetics, including clotting time (CT) and clot formation time (CFT).
Target-specific activity assays-such as FXI/FXIa inhibition-further enable direct assessment of pharmacological engagement, bridging the gap between exposure and functional outcomes.
This integrated dataset strengthens confidence in both efficacy and safety profiling, particularly for regulatory interactions.
Translational Case Study: Anti-FXI Antibody Development
The translational value of this platform has been demonstrated in collaborative programs with leading pharmaceutical partners. In a representative study involving an anti-FXI monoclonal antibody (e.g., BJTJ-1837), the NHP AV-shunt model confirmed potent, dose-dependent inhibition of thrombus formation.
Notably, this antithrombotic effect was achieved without a corresponding increase in bleeding risk in the forearm vein model. These findings highlight the therapeutic potential of FXI-targeting strategies to dissociate thrombosis prevention from bleeding complications.
The study results were subsequently published in Research and Practice in Thrombosis and Haemostasis, underscoring the scientific credibility of the model and its outputs.
Conclusion
The integration of the NHP AV-shunt thrombosis model with standardized bleeding assessment and comprehensive coagulation analytics provides a robust and translationally relevant framework for evaluating antibody-based antithrombotic therapies.
With standardized operating procedures, high reproducibility, and extensive IND-enabling experience, Prisys Biotechnologies supports global biopharmaceutical partners in advancing coagulation-targeting therapeutics from preclinical development toward clinical success.
FAQ
Q: Why are NHP models preferred for evaluating antithrombotic antibody drugs?
A: NHPs share high physiological and molecular similarity with humans in coagulation pathways and immune responses, making them more predictive than rodent models for biologics, particularly monoclonal antibodies.
Q: What makes the AV-shunt model translationally relevant?
A: The AV-shunt model simultaneously activates platelet aggregation and coagulation cascades under controlled flow conditions, closely mimicking human thrombosis mechanisms and enabling quantitative assessment of drug efficacy.
Q: How is bleeding risk assessed alongside antithrombotic efficacy?
A: Bleeding risk is evaluated using a standardized forearm vein bleeding model, which measures bleeding time and blood loss. This method allows repeated measurements and provides a reliable assessment of drug-induced hemostatic impairment.
